Last10K.com

Eloxx Pharmaceuticals, Inc. (ELOX) SEC Filing 8-K Material Event for the period ending Tuesday, January 9, 2024

Eloxx Pharmaceuticals, Inc.

HISTORY TOOLS
CIK: 1035354 Ticker: ELOX

View differences made from one to another to evaluate Eloxx Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Eloxx Pharmaceuticals, Inc..

Continue

Assess how Eloxx Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Eloxx Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2024 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Cover
Ticker: ELOX
CIK: 1035354
Form Type: 8-K Corporate News
Accession Number: 0001104659-24-002631
Submitted to the SEC: Tue Jan 09 2024 5:10:15 PM EST
Accepted by the SEC: Tue Jan 09 2024
Period: Tuesday, January 9, 2024
Industry: Commercial Physical And Biological Research
Events:
  1. New Agreement
  2. Unregistered Sales

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/elox/0001104659-24-002631.htm